Haemonetics (HAE) Misses Q4 EPS by 5c; Guides FY16 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Haemonetics (HAE) Strong Sell Rating Removed at Off Wall Street
April 28, 2015 11:11 AM EDTHaemonetics's (NYSE: HAE) Strong Sell recommendation was removed at Off Wall Street after the company reported Q4 results and guidance, according to sources. Analysts noted FY16 guidance implies revenue and EPS growth.
... MoreBarrington Research Downgrades Haemonetics (HAE) to Market Perform
April 28, 2015 9:38 AM EDTBarrington Research downgraded Haemonetics (NYSE: HAE) from Outperform to Market Perform with a price target of $44.00. The change follows Q4 results and guidance.
Analyst Michael Petusky, "While we like many aspects of the Haemonetics story, particularly longer term, we do not see the... More
Haemonetics (HAE) PT Lifted at Jefferies Despite FX Hit
April 28, 2015 8:38 AM EDTJefferies analyst Anthony Petrone reiterated a Buy rating and bumped his price target on Haemonetics (NYSE: HAE) to $48.00 (from $45.00) following Q4 results. The analyst said while FX was unavoidable the underlying trends support a rebound in FY16.
Petrone commented, "HAE... More
